GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

GenSight Biologics S.A.

GenSight Biologics  is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

	Dec '14	Jun '15	Dec '15	Dec '16	Jun '17	Dec '17	Jun '18	Dec '18	Jun '19	Dec '19	Jun '20	Dec '20	Jun '21	Dec '21	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23
asset turnover																0.01 -		0.08 -	0.09 14.14%	0.01 85.34%
cash conversion cycle																			-5.01K -
cash per share																0.23 -		0.02 -	0.02 0.00%	0.04 90.47%
company equity multiplier	1.40 -	1.85 32.03%	1.24 33.05%	1.11 10.31%	1.12 0.66%	1.13 1.21%	1.18 4.56%	1.55 30.97%	2.02 30.44%	2.77 36.86%	-60.07 2,272.19%	4.06 106.76%	2.05 49.56%	3.54 73.00%	12.65 257.12%	-1.70 113.42%	-1.70 0%	-0.62 63.60%	-0.62 0.00%	-0.30 51.87%
days of inventory outstanding																			0.00 -
days of payables outstanding																			5.30K -
days of sales outstanding																		2.58 -	292.94 11,233.52%	0.73 99.75%
dividend yield
ebit per revenue																-25.71 -		-6.29 -	-11.78 87.18%	-50.81 331.36%	-9.06 82.17%
ebt per ebit																1.07 -		0.70 -	0.72 2.74%	1.13 57.41%	1.12 0.65%
effective tax rate																-0.00 -		-0.00 -	0.09 53,130.02%	-0.00 100.16%	0.04 25,871.08%
enterprise value multiple																-19.16 -		-12.87 -	-2.79 78.35%	-9.27 232.87%
fixed asset turnover																0.14 -		0.88 -	1.00 14.14%	0.06 93.89%
free cash flow per share																-0.19 -		-0.18 -	-0.36 103.34%	-0.08 76.59%
gross profit margin																1 -		1 -	0.88 12.39%	1 14.14%	1 0%
interest coverage																			-13.60 -
inventory turnover																			192K -
long term debt to capitalization	0.06 -	0.10 68.89%	0.02 78.19%	0.05 150.02%	0.04 24.61%	0.05 33.46%	0.07 35.67%	0.13 77.68%	0.18 42.29%	0.36 98.61%	1.05 193.81%	0.50 52.58%	0.21 57.11%	0.31 45.29%	0.60 92.64%	-17.66 3,064.45%	-2.02 88.56%	-0.25 87.79%	-0.02 90.12%	-0.25 928.98%
net income per ebt																1.00 -		1.00 -	0.91 8.88%	1.00 9.72%	0.96 3.61%
net profit margin																-27.54 -		-4.40 -	-7.72 75.23%	-57.49 644.96%	-9.82 82.92%
operating cash flow per share																-0.18 -		-0.18 -	-0.36 103.34%	-0.08 76.62%
operating cycle																			292.94 -
operating profit margin																-25.71 -		-6.29 -	-11.78 87.18%	-50.81 331.36%	-9.06 82.17%
payables turnover																			0.02 -
pretax profit margin																-27.54 -		-4.40 -	-8.47 92.31%	-57.50 579.00%	-10.19 82.28%
price fair value																-10.49 -		-4.03 -	-1.27 68.41%	-1.07 16.30%
receivables turnover																		34.82 -	0.31 99.12%	124 40,260%
return on assets																-0.33 -		-0.36 -	-0.71 100%	-0.78 9.20%
return on capital employed																-0.70 -		0.62 -	1.32 113.64%	0.39 70.42%
return on equity																0.55 -		0.22 -	0.44 99.99%	0.23 47.45%
total debt to capitalization	0.06 -	0.10 68.89%	0.02 78.19%	0.05 150.02%	0.04 24.61%	0.05 33.46%	0.07 35.67%	0.13 77.68%	0.21 66.89%	0.40 91.91%	1.04 157.26%	0.55 46.71%	0.30 45.96%	0.44 47.18%	0.77 76.06%	-17.66 2,378.92%	-4.81 72.78%	-0.25 94.87%	-1.45 489.62%	-2.87 97.10%

EURONEXT:SIGHT

GenSight Biologics S.A.

Last Close

0.40

30/08 15:35

Market Cap

31.04M

Beta: 2.21

Volume Today

355.02K

Avg: 307.85K

PE Ratio

−0.65

PFCF: −0.75

Preview